The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small cell lung cancer with wild type EGFR (OLCSG1202).
 
Akihiro Bessho
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen; AstraZeneca; Bayer Yakuhin; Kyorin; Ono Pharmaceutical; Pfizer; Taisho Toyama Pharma
 
Nobuaki Ochi
No Relationships to Disclose
 
Shoichi Kuyama
No Relationships to Disclose
 
Nobukazu Fujimoto
Consulting or Advisory Role - Kissei Pharmaceutical
Research Funding - Hisamitsu Pharmaceutical; MSD; Ono Pharmaceutical
 
Takahiro Umeno
No Relationships to Disclose
 
Kiichiro Ninomiya
Honoraria - AstraZeneca; Lilly
 
Genyo Ikeda
No Relationships to Disclose
 
Daijiro Harada
Speakers' Bureau - Bristol-Myers Squibb Japan; Kyowa Hakko Kirin; Ono Pharmaceutical; Yakult Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca Japan; Bristol-Myers Squibb Japan; Ono Pharmaceutical
 
Daizo Kishino
No Relationships to Disclose
 
Shinobu Hosokawa
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
 
Kenichi Chikamori
No Relationships to Disclose
 
Naoyuki Nogami
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical
 
Shingo Harita
No Relationships to Disclose
 
Hiroshi Ueoka
Honoraria - Astellas Pharma; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Teijin Pharma
 
Katsuyuki Hotta
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Nihonkayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical
 
Nagio Takigawa
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Nihonkayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Mitsune Tanimoto
No Relationships to Disclose
 
Katsuyuki Kiura
Honoraria - Chugai Pharma; Lilly Japan; Pfizer
Research Funding - AstraZeneca Japan; Boehringer Ingelheim; Daiichi Sankyo; Nihonkayaku; Shionogi